查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070558

硬皮症治療市場規模、佔有率、成長、全球產業分析、區域洞察與 2026-2034 年預測。

Scleroderma Therapeutics Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

硬皮症治療市場的成長要素

2025年全球硬皮症治療市場規模為18.3億美元，預計將從2026年的19.8億美元成長至2034年的35.2億美元，預測期內複合年成長率（CAGR）為7.45%。北美地區在2025年佔市場主導地位，市場佔有率達40.43%，這得益於其先進的醫療基礎設施、較高的診斷率、強大的專家網路以及系統性硬皮症及其併發症創新療法的日益普及。

硬皮症（也稱為系統性硬皮症）是一種罕見的自體免疫疾病，其特徵是纖維化、血管異常和免疫功能障礙，可涉及皮膚、肺、心臟、腎臟和消化器官系統。隨著人們對此疾病的認知不斷提高、早期診斷的普及以及系統性硬皮症相關間質性肺病（SSc-ILD）等嚴重併發症率的上升，對先進治療方案的需求日益成長。市場正逐步從症狀管理轉向標靶治療和疾病修正治療。

在這個市場運作的主要公司包括勃林格殷格翰國際有限公司、羅氏製藥有限公司、協和麒麟株式會社、諾華公司、高德美公司、Adicet Bio、Zura Bio Ltd.和Certa Therapeutics。

市場趨勢

對標靶治療的日益重視正在推動創新。

塑造全球市場的關鍵趨勢之一是日益關注針對系統性硬皮症潛在免疫和纖維化機制的標靶治療。製藥公司正大力投資生物製藥、細胞療法和先進的免疫調節療法，這些療法比傳統的免疫抑制療法更精準。這種向基於機制的療法的轉變有望改善治療效果，並創造長期成長機會。

市場促進因素

系統性硬皮症負擔加重，推動了市場成長。

系統性硬皮症盛行率的不斷上升，以及肺動脈高壓、間質性肺病、消化器官系統疾病和腎功能損害等相關器官併發症的增加，顯著提高了對治療性介入的需求。醫療專業人員正著重強調早期診斷和積極的治療策略，以延緩疾病進展並改善患者預後。

持續的研究活動和不斷擴大的臨床開發項目也促進了市場成長。各公司正積極開發創新療法，以滿足罹患嚴重疾患者的未滿足需求。

市場限制因素

可用於疾病修正治療選擇有限。

影響市場成長的主要阻礙因素之一是目前可用於延緩系統性硬皮症整體進展的治療選擇有限。許多現有療法主要著重於控制症狀和解決器官特異性併發症，而非針對潛在疾病的進展。

此外，一些後期臨床試驗未能證明其具有顯著療效，凸顯了在自體免疫疾病這一複雜領域開發突破性療法的挑戰。

市場機遇

巨大的未滿足需求創造了巨大的成長潛力。

由於缺乏廣泛有效的疾病修正治療，該市場存在巨大的機會。目前的治療方法主要針對纖維化、發炎和血管併發症，因此，對綜合疾病管理的需求仍遠未滿足。

監管支持，例如簡審類和孤兒藥優先待遇，正鼓勵製藥公司投資創新療法。生技公司日益成長的興趣和臨床研發管線的活性化預計將在預測期內創造新的商業性機會。

細分分析

藥物類別

到2025年，免疫抑制劑市場將佔主導地位，這主要得益於Mycophenolate Mofetil、Cyclophosphamide和Rituximab等療法的廣泛應用，這些療法用於控制發炎和器官損傷。這些藥物在治療進行性疾病患者的策略中繼續發揮核心作用。

預計白細胞介素-6 (IL-6) 抑制劑細分市場將實現最快成長，到 2034 年將以 11.57% 的複合年成長率成長，這主要得益於生物目標的日益普及。

疾病特異性

預計到2025年，系統性硬皮症領域將佔最大的市場佔有率。這是因為該疾病病情嚴重，會影響多個器官，並且需要長期治療。

預計在預測期內，局部硬皮症細分市場將以 5.17% 的複合年成長率成長。

按年齡層

到2025年，成人市場將佔主導地位。這是因為系統性硬皮症主要發生於成人，並且需要持續的治療和管理。

受老年人診斷率上升的推動，老年人群體預計將以 8.46% 的複合年成長率成長。

按類型

到 2025 年，品牌藥品市場將佔最大的市場佔有率，這主要得益於 OFEV 和先進生物製藥等高階療法的強勁市場表現。

預計到 2034 年，學名藥市場將以 5.75% 的複合年成長率成長。

透過行政途徑

由於口服給藥方式方便、患者遵守用藥性高以及適合長期門診治療，因此口服給藥方式佔了市場主導地位。

預計其他行政路線段在預測期內將以 10.47% 的複合年成長率成長。

透過分銷管道

到 2025 年，零售藥局領域將佔最大的市場佔有率，這得益於慢性病治療和管理需求的成長以及患者獲得專科藥物的途徑的改善。

預計到 2034 年，線上藥局領域將以最高的成長率成長，複合年成長率將達到 11.83%。

區域展望

北美洲

北美在全球市場中處於領先地位，預計到 2025 年市場規模將達到 7.4 億美元。該地區擁有許多優勢，例如先進的診斷能力、健全的保險報銷體係以及便捷的專科醫療服務。

  • 美國市場規模（2026年）：7.2億美元

歐洲

預計歐洲市場將以6.97%的複合年成長率成長，到2026年達到5.6億美元。多學科治療方法和早期篩檢計畫的日益普及是推動市場成長的主要因素。

  • 德國市場規模（2026年）：1.4億美元
  • 英國市場規模（2026年）：1.1億美元

亞太地區

預計到 2026 年，亞太地區的市場規模將達到 4.3 億美元，這主要得益於人們意識的提高、診斷能力的增強以及醫療保健服務覆蓋範圍的擴大。

  • 中國市場規模（2026年）：1.4億美元
  • 日本市場規模（2026年）：9,000萬美元
  • 印度市場規模（2026年）：4,000萬美元

拉丁美洲、中東和非洲

由於人們對罕見自體免疫疾病的認知不斷提高，以及獲得專業治療的機會不斷改善，預計這些地區將逐步發展壯大。

  • 拉丁美洲市場規模（2026年）：1.3億美元
  • 海灣合作理事會市場規模（2026年）：3,000萬美元
  • 南非市場規模（2026年）：2,000萬美元

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • 主要地區和國家主要疾病的流行情況
  • 大型公司管道分析
  • 新產品發布：按主要公司分類
  • 主要地區和國家的監管情況概述
  • 產業重大發展動態（合併、收購、合作、新產品發布等）

第5章：2021-2034年全球硬皮症治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 內皮素受體拮抗劑（ERA）
    • 磷酸二酯酶-5 (PDE-5) 抑制劑
    • 前列腺環素通路促效劑
    • 免疫抑制劑
    • 白細胞介素-6 (IL-6) 抑制劑
    • 抗纖維化藥物
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 系統性硬皮症
    • 局部硬皮症
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
    • 老年人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 學名藥
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 靜脈
    • 皮下
    • 外用
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美硬皮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲硬皮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區硬皮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲硬皮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲硬皮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Cumberland Pharmaceuticals Inc.
    • Kyowa Kirin Co., Ltd.
    • GALDERMA
    • Zura Bio Ltd.
    • Adicet Bio
    • Certa Therapeutics
Product Code: FBI116084

Growth Factors of scleroderma therapeutics Market

The global scleroderma therapeutics market was valued at USD 1.83 billion in 2025 and is projected to grow from USD 1.98 billion in 2026 to USD 3.52 billion by 2034, registering a CAGR of 7.45% during the forecast period. North America dominated the market with a 40.43% share in 2025, supported by advanced healthcare infrastructure, higher diagnosis rates, strong specialist networks, and increasing adoption of innovative therapies for systemic sclerosis and related complications.

Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease characterized by fibrosis, vascular abnormalities, and immune dysfunction that can affect the skin, lungs, heart, kidneys, and gastrointestinal system. Growing awareness, earlier diagnosis, and increasing prevalence of severe complications such as systemic sclerosis-associated interstitial lung disease (SSc-ILD) are driving demand for advanced therapeutic solutions. The market is gradually shifting from symptom management toward targeted and disease-modifying treatment approaches.

Major companies operating in the market include Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Kyowa Kirin Co., Ltd., Novartis AG, GALDERMA, Adicet Bio, Zura Bio Ltd., and Certa Therapeutics.

Market Trends

Rising Focus on Targeted Therapies Driving Innovation

A major trend shaping the global market is the increasing focus on targeted therapies designed to address the underlying immune and fibrotic mechanisms of systemic sclerosis. Pharmaceutical companies are investing heavily in biologics, cell therapies, and advanced immunomodulatory treatments that offer greater precision than conventional immunosuppressive therapies. This transition toward mechanism-based therapies is expected to improve treatment outcomes and create long-term growth opportunities.

Market Drivers

Increasing Burden of Systemic Sclerosis Supporting Market Growth

The rising incidence of systemic sclerosis and associated organ complications such as pulmonary arterial hypertension, interstitial lung disease, gastrointestinal disorders, and renal involvement is significantly increasing demand for therapeutic interventions. Healthcare providers are emphasizing early diagnosis and proactive treatment strategies to slow disease progression and improve patient outcomes.

Ongoing research activities and expanding clinical development programs are also contributing to market expansion. Companies are actively developing innovative therapies to address the unmet medical needs of patients suffering from severe disease manifestations.

Market Restraints

Limited Availability of Disease-Modifying Therapies

One of the major restraints affecting market growth is the limited availability of therapies capable of modifying the overall progression of systemic sclerosis. Most currently available treatments primarily focus on symptom management or organ-specific complications rather than addressing the underlying disease process.

In addition, several late-stage clinical trials have failed to demonstrate significant efficacy, highlighting the challenges associated with developing breakthrough therapies in this complex autoimmune disease segment.

Market Opportunities

High Unmet Need Creating Significant Growth Potential

The market presents substantial opportunities due to the lack of broadly effective disease-modifying therapies. Current treatment approaches mainly target fibrosis, inflammation, and vascular complications individually, leaving significant unmet needs for comprehensive disease management.

Regulatory support, including Fast Track Designations and orphan drug incentives, is encouraging pharmaceutical companies to invest in innovative therapies. Growing interest from biotechnology firms and increasing clinical pipeline activity are expected to generate new commercial opportunities over the forecast period.

Segmentation Analysis

By Drug Class

The immunosuppressants segment dominated the market in 2025 due to widespread use of therapies such as mycophenolate mofetil, cyclophosphamide, and rituximab for controlling inflammation and organ involvement. These drugs remain central to treatment strategies for patients with progressive disease.

The interleukin-6 (IL-6) inhibitors segment is expected to register the fastest growth, expanding at a CAGR of 11.57% through 2034 due to increasing adoption of targeted biologic therapies.

By Disease Indication

The systemic scleroderma segment held the largest market share in 2025 because of its severe disease burden and involvement of multiple organs requiring long-term treatment.

The localized scleroderma segment is projected to grow at a CAGR of 5.17% during the forecast period.

By Age Group

The adult segment dominated the market in 2025, as systemic sclerosis primarily affects adults and requires continuous therapeutic management.

The geriatric segment is expected to grow at a CAGR of 8.46%, supported by increasing diagnosis rates among older populations.

By Type

The branded segment accounted for the largest market share in 2025 due to the strong presence of premium therapies such as OFEV and advanced biologic treatments.

The generic segment is projected to grow at a CAGR of 5.75% through 2034.

By Route of Administration

The oral segment dominated the market due to convenience, better patient compliance, and suitability for long-term outpatient treatment.

The other routes segment is expected to grow at a CAGR of 10.47% during the forecast period.

By Distribution Channel

The retail pharmacies segment held the largest share in 2025, supported by the increasing need for chronic therapy management and improved patient access to specialty medications.

The online pharmacies segment is projected to grow at the fastest CAGR of 11.83% through 2034.

Regional Outlook

North America

North America dominated the global market and was valued at USD 0.74 billion in 2025. The region benefits from advanced diagnostic capabilities, strong reimbursement systems, and greater access to specialist care.

  • U.S. market size (2026): USD 0.72 billion

Europe

Europe is projected to grow at a CAGR of 6.97% and reach USD 0.56 billion in 2026. Growing adoption of multidisciplinary treatment approaches and early screening programs is supporting market growth.

  • Germany market size (2026): USD 0.14 billion
  • U.K. market size (2026): USD 0.11 billion

Asia Pacific

Asia Pacific is expected to reach USD 0.43 billion in 2026, supported by improving awareness, better diagnostic capabilities, and expanding healthcare access.

  • China market size (2026): USD 0.14 billion
  • Japan market size (2026): USD 0.09 billion
  • India market size (2026): USD 0.04 billion

Latin America and Middle East & Africa

These regions are expected to witness moderate growth due to increasing awareness of rare autoimmune diseases and improving access to specialized treatment.

  • Latin America market size (2026): USD 0.13 billion
  • GCC market size (2026): USD 0.03 billion
  • South Africa market size (2026): USD 0.02 billion

Competitive Landscape

The global scleroderma therapeutics market is semi-consolidated, with leading companies focusing on clinical research, regulatory approvals, pipeline expansion, and strategic collaborations. Major players continue investing in innovative biologics, targeted therapies, and disease-modifying treatments to strengthen their market positions.

Research collaborations, Fast Track Designations, label expansions, and rare disease-focused development strategies are expected to intensify competition over the coming years.

Key Industry Developments

  • February 2026: Boehringer Ingelheim acquired an exclusive license for a novel preclinical autoimmune disease program from Sitryx Therapeutics.
  • February 2026: Adicet Bio received U.S. FDA Fast Track Designation for ADI-001 for systemic sclerosis treatment.
  • October 2025: Merck received FDA approval for WINREVAIR for pulmonary arterial hypertension management.
  • July 2025: Adicet Bio dosed the first systemic sclerosis patient in the second cohort of its Phase 1 ADI-001 trial.
  • June 2025: Galderma initiated two clinical trials evaluating nemolizumab in systemic sclerosis patients.
  • December 2024: Zura Bio launched the Phase 2 TibuSURE study evaluating tibulizumab for systemic sclerosis.

Conclusion

The global scleroderma therapeutics market is expected to expand significantly from USD 1.83 billion in 2025 to USD 1.98 billion in 2026 and reach USD 3.52 billion by 2034. Rising prevalence of systemic sclerosis, growing awareness of early diagnosis, increasing demand for targeted therapies, and strong clinical pipeline activity are driving market growth. Although limited disease-modifying treatment options and complex clinical trial requirements remain challenges, continuous innovation in biologics, cell therapies, and precision medicine is expected to create substantial opportunities and support long-term market expansion.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Endothelin Receptor Antagonists (ERAs)

  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Prostacyclin Pathway Agents
  • Immunosuppressants
  • Interleukin-6 (IL-6) Inhibitors
  • Antifibrotic Agents
  • Others

By Disease Indication * Systemic Scleroderma

  • Localized Scleroderma

By Age Group * Pediatric

  • Adult
  • Geriatric

By Type * Branded

  • Generic

By Route of Administration * Oral

  • Intravenous
  • Subcutaneous
  • Topical
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Regions/ Countries
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Overview of Regulatory Scenario, By Key Regions/ Countries
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Endothelin Receptor Antagonists (ERAs)
    • 5.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 5.1.3. Prostacyclin Pathway Agents
    • 5.1.4. Immunosuppressants
    • 5.1.5. Interleukin-6 (IL-6) Inhibitors
    • 5.1.6. Antifibrotic Agents
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Systemic Scleroderma
    • 5.2.2. Localized Scleroderma
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adult
    • 5.3.3. Geriatric
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generics
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Intravenous
    • 5.5.3. Subcutaneous
    • 5.5.4. Topical
    • 5.5.5. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies
    • 5.6.3. Online Pharmacies
    • 5.6.4. Others
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Endothelin Receptor Antagonists (ERAs)
    • 6.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.1.3. Prostacyclin Pathway Agents
    • 6.1.4. Immunosuppressants
    • 6.1.5. Interleukin-6 (IL-6) Inhibitors
    • 6.1.6. Antifibrotic Agents
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Systemic Scleroderma
    • 6.2.2. Localized Scleroderma
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adult
    • 6.3.3. Geriatric
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generics
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Intravenous
    • 6.5.3. Subcutaneous
    • 6.5.4. Topical
    • 6.5.5. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies
    • 6.6.3. Online Pharmacies
    • 6.6.4. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Endothelin Receptor Antagonists (ERAs)
    • 7.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 7.1.3. Prostacyclin Pathway Agents
    • 7.1.4. Immunosuppressants
    • 7.1.5. Interleukin-6 (IL-6) Inhibitors
    • 7.1.6. Antifibrotic Agents
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Systemic Scleroderma
    • 7.2.2. Localized Scleroderma
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adult
    • 7.3.3. Geriatric
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generics
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Intravenous
    • 7.5.3. Subcutaneous
    • 7.5.4. Topical
    • 7.5.5. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies
    • 7.6.3. Online Pharmacies
    • 7.6.4. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Endothelin Receptor Antagonists (ERAs)
    • 8.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 8.1.3. Prostacyclin Pathway Agents
    • 8.1.4. Immunosuppressants
    • 8.1.5. Interleukin-6 (IL-6) Inhibitors
    • 8.1.6. Antifibrotic Agents
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Systemic Scleroderma
    • 8.2.2. Localized Scleroderma
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adult
    • 8.3.3. Geriatric
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generics
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Intravenous
    • 8.5.3. Subcutaneous
    • 8.5.4. Topical
    • 8.5.5. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies
    • 8.6.3. Online Pharmacies
    • 8.6.4. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Endothelin Receptor Antagonists (ERAs)
    • 9.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 9.1.3. Prostacyclin Pathway Agents
    • 9.1.4. Immunosuppressants
    • 9.1.5. Interleukin-6 (IL-6) Inhibitors
    • 9.1.6. Antifibrotic Agents
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Systemic Scleroderma
    • 9.2.2. Localized Scleroderma
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adult
    • 9.3.3. Geriatric
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generics
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Intravenous
    • 9.5.3. Subcutaneous
    • 9.5.4. Topical
    • 9.5.5. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies
    • 9.6.3. Online Pharmacies
    • 9.6.4. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Scleroderma Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Endothelin Receptor Antagonists (ERAs)
    • 10.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 10.1.3. Prostacyclin Pathway Agents
    • 10.1.4. Immunosuppressants
    • 10.1.5. Interleukin-6 (IL-6) Inhibitors
    • 10.1.6. Antifibrotic Agents
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Systemic Scleroderma
    • 10.2.2. Localized Scleroderma
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adult
    • 10.3.3. Geriatric
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generics
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Intravenous
    • 10.5.3. Subcutaneous
    • 10.5.4. Topical
    • 10.5.5. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Online Pharmacies
    • 10.6.4. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Boehringer Ingelheim International GmbH
    • 11.2.2. F. Hoffmann-La Roche Ltd
    • 11.2.3. Novartis AG
    • 11.2.4. Cumberland Pharmaceuticals Inc.
    • 11.2.5. Kyowa Kirin Co., Ltd.
    • 11.2.6. GALDERMA
    • 11.2.7. Zura Bio Ltd.
    • 11.2.8. Adicet Bio
    • 11.2.9. Certa Therapeutics

List of Tables

  • Figure 1: Global Scleroderma Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Scleroderma Therapeutics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Scleroderma Therapeutics Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Scleroderma Therapeutics Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Scleroderma Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Scleroderma Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Scleroderma Therapeutics Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 14: North America Scleroderma Therapeutics Market Value Share (%), by Age Group 2025
  • Figure 15: North America Scleroderma Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 16: North America Scleroderma Therapeutics Market Value Share (%), by Type, 2025
  • Figure 17: North America Scleroderma Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Scleroderma Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Scleroderma Therapeutics Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Scleroderma Therapeutics Market Value Share (%), by Country, 2025
  • Figure 23: Europe Scleroderma Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Scleroderma Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 26: Europe Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 27: Europe Scleroderma Therapeutics Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 28: Europe Scleroderma Therapeutics Market Value Share (%), by Age Group 2025
  • Figure 29: Europe Scleroderma Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Europe Scleroderma Therapeutics Market Value Share (%), by Type, 2025
  • Figure 31: Europe Scleroderma Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Scleroderma Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Scleroderma Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Scleroderma Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 42: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Age Group 2025
  • Figure 43: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 44: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Type, 2025
  • Figure 45: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Scleroderma Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Scleroderma Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Scleroderma Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Scleroderma Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 54: Latin America Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 55: Latin America Scleroderma Therapeutics Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 56: Latin America Scleroderma Therapeutics Market Value Share (%), by Age Group 2025
  • Figure 57: Latin America Scleroderma Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 58: Latin America Scleroderma Therapeutics Market Value Share (%), by Type, 2025
  • Figure 59: Latin America Scleroderma Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Scleroderma Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Scleroderma Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Scleroderma Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 68: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 69: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 70: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Age Group 2025
  • Figure 71: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 72: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Type, 2025
  • Figure 73: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Scleroderma Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Scleroderma Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Scleroderma Therapeutics Market Share (%), by Company, 2025